Somatostatin Analogs
The peptide family anchored by somatostatin (SRIF, isolated by Brazeau and Vale at the Salk Institute in 1973) and its long-acting synthetic analogs — octreotide (Sandostatin), lanreotide (Somatuline), pasireotide (Signifor) — used clinically for acromegaly, neuroendocrine tumors, Cushing's disease, and post-operative pancreatic fistula prophylaxis. The endogenous family also includes cortistatin, the somatostatin paralog with overlapping but distinct pharmacology.
Somatostatin and its synthetic analogs make up one of the most clinically established peptide drug families in modern endocrinology. Native somatostatin (somatotropin release-inhibiting factor, SRIF) is a 14- or 28-residue peptide isolated from sheep hypothalamus by Paul Brazeau, Wylie Vale, Roger Burgus, Roger Guillemin, and colleagues at the Salk Institute, with the foundational 1973 Science paper (Brazeau et al., Science 1973) reporting its inhibition of pituitary growth hormone secretion. The peptide turned out to be a broad inhibitor of secretion across multiple endocrine and exocrine systems — growth hormone, TSH, insulin, glucagon, gastrin, secretin, VIP, gastric acid, pancreatic exocrine secretions, gallbladder contraction — and to act through five G-protein-coupled receptors (sst1-sst5, cloned in the early 1990s) with characteristic tissue distributions and ligand selectivities.
The synthetic analog era began with octreotide (Sandostatin, Sandoz/Novartis, FDA-approved 1988), an 8-residue cyclic somatostatin analog with sst2/sst5 selectivity and sufficient resistance to peptidase degradation for clinical dosing. Octreotide reshaped acromegaly care, established the somatostatin-analog class for neuroendocrine tumor (NET) management, and became the foundational tool of the field. Lanreotide (Somatuline, Ipsen, FDA-approved 2007) extended the class with a depot formulation enabling monthly dosing, and pasireotide (Signifor, Novartis, FDA-approved 2012) expanded the receptor selectivity to include sst1 and sst3 — the basis for its Cushing's disease indication and its different efficacy profile in some NET subtypes. The endogenous family also includes cortistatin, a somatostatin paralog discovered in 1996 that shares the FWKT receptor-binding pharmacophore plus the broader sst1-sst5 receptor agonism with somatostatin, but with additional ghrelin-receptor antagonism and selective expression in cortical/hippocampal interneurons (see the Cortistatin peptide page for the full account). The class has continued to evolve through the 2010s and 2020s with peptide receptor radionuclide therapy (PRRT) using radiolabeled octreotide analogs (Lutathera, Netter-1 trial), oral octreotide formulations (Mycapssa, FDA-approved 2020), and ongoing expansion in NET management.
This page is the family-level pillar covering the somatostatin agonist class as a whole. For individual peptide pages with full evidence ratings, dosing, and references, follow the links to each member below.
Peptides in Somatostatin Analogs
Lanreotide
Somatostatin Analog / SSTR2/5 Agonist
An FDA-approved long-acting somatostatin analog used to treat acromegaly, gastroenteropancreatic neuroendocrine tumors, and carcinoid syndrome.
Octreotide
Somatostatin Analogue
An FDA-approved somatostatin analogue used to treat acromegaly, carcinoid tumors, and severe diarrhea.
Pasireotide
Pan-Somatostatin Analog / SSTR1/2/3/5 Agonist
An FDA-approved pan-somatostatin analog (SSTR1/2/3/5) used as first-line medical therapy for Cushing's disease and second-line for acromegaly.
Somatostatin
Neuropeptide / Growth Hormone-Inhibiting Hormone
The endogenous cyclic neuropeptide (SST-14 and SST-28 isoforms) that acts as the body's universal inhibitor of hormone and exocrine secretion — the physiological parent of the approved analogs octreotide, lanreotide, and pasireotide.
Cortistatin
Neuropeptide
An endogenous somatostatin-family neuropeptide identified in 1996 by Luis de Lecea and J. Gregor Sutcliffe at the Scripps Research Institute, expressed in cortical and hippocampal GABAergic interneurons and signaling through all five somatostatin receptors plus the ghrelin receptor and a separate cortistatin-preferring binding site, with distinctive roles in slow-wave sleep, neuronal depression, and immune anti-inflammatory regulation that distinguish it from somatostatin despite extensive pharmacological overlap.
Other members of the class
Somatostatin-28 (SS-28)
The 28-residue tissue-specific alternative processing product of the same prepropeptide that produces somatostatin-14. Different tissue distribution, similar receptor pharmacology. Not therapeutically administered separately.
177Lu-DOTATATE / 177Lu-DOTATOC (Lutathera, peptide receptor radionuclide therapy)
Radiolabeled octreotide analogs that bind sst2-expressing NET cells and deliver targeted beta-particle radiation. Lutathera (177Lu-DOTATATE) FDA-approved 2018 based on NETTER-1 trial. Not tracked as a standalone peptide entry but mechanistically a member of the somatostatin-analog family.
Mycapssa (oral octreotide capsules)
Chiasma/Amryt's permeability-enhancer-based oral octreotide formulation, FDA-approved 2020 for acromegaly maintenance. Same molecule as injectable octreotide, different formulation.
Pegvisomant (Somavert)
GH-receptor antagonist for acromegaly cases inadequate on somatostatin analogs. Not a somatostatin analog mechanistically — different drug class, complementary clinical role.
Shared mechanism
The somatostatin family signals through five G-protein-coupled receptors — sst1, sst2, sst3, sst4, sst5 — that couple primarily to Gi/o, lowering cAMP and inhibiting downstream secretory and proliferative pathways. The receptor distributions are tissue-characteristic: sst2 is the principal pituitary somatotroph receptor (the basis for acromegaly indications) and the dominant receptor on most well-differentiated neuroendocrine tumors (the basis for NET indications and PRRT imaging/therapy). sst5 is enriched on corticotroph adenomas in Cushing's disease (the basis for pasireotide's Cushing's indication) and on some NET subtypes. sst1, sst3, and sst4 have more restricted clinical roles but contribute to the broader pharmacology of the class.
Downstream effects of sst1-sst5 agonism span the full somatostatin pharmacology: inhibition of pituitary GH and TSH secretion (acromegaly, TSH-secreting adenoma); inhibition of pancreatic insulin and glucagon secretion (glucose dysregulation as a class side effect); inhibition of gastrointestinal hormones including gastrin, secretin, VIP, and pancreatic polypeptide (the basis for VIPoma symptom control); inhibition of gastric acid secretion and gallbladder contraction (gallstone risk as a class side effect); inhibition of pancreatic exocrine secretion (the basis for post-operative pancreatic fistula prophylaxis use); and antiproliferative effects on sst2-expressing tumor cells (the disease-modifying effect documented in CLARINET for lanreotide).
Receptor selectivity differences across the synthetic analogs explain their differential clinical positioning. Octreotide and lanreotide have sst2/sst5 selectivity — strong on the dominant pituitary somatotroph and NET receptor, modest on corticotroph and other receptors. Pasireotide adds significant sst1 and sst3 activity — broader receptor profile underlying its Cushing's efficacy but also producing more pronounced glucose dysregulation as a side effect (since sst5 plays a larger role in glucose-stimulated insulin release than sst2). Cortistatin (the endogenous paralog) has full sst1-sst5 agonism plus ghrelin-receptor antagonism. Specific receptor-subtype-selective analogs have been developed as research tools but have not produced widely-used clinical agents.
Pharmacokinetic engineering has progressed from short-acting subcutaneous (octreotide thrice daily, ~100 minute half-life) through monthly depot (octreotide LAR, lanreotide autogel) to oral (Mycapssa permeability-enhancer formulation) and radiolabeled (Lutathera 177Lu-DOTATATE PRRT). The depot formulations rely on biodegradable polymer or supramolecular gel matrices for sustained release rather than the albumin-binding fatty-acid modifications used in long-acting incretin-class drugs.
History & discovery
Somatostatin's discovery emerged from Roger Guillemin's competitive race with Andrew Schally to identify the hypothalamic factors regulating pituitary hormone secretion. Guillemin's group at the Salk Institute in San Diego — including Paul Brazeau, Wylie Vale, Roger Burgus, and others — had been searching for a growth hormone-inhibiting factor that the pituitary biology suggested must exist. The 1973 Science paper (Brazeau et al., PMID 4682131) reported the isolation, characterization, and naming of somatostatin (somatotropin release-inhibiting factor) from sheep hypothalamus extracts, demonstrating dose-dependent inhibition of pituitary growth hormone secretion. The work earned Guillemin a share of the 1977 Nobel Prize in Physiology or Medicine alongside Schally and Rosalyn Yalow. The 14-residue cyclic peptide (Ala-Gly-Cys-Lys-Asn-Phe-Phe-Trp-Lys-Thr-Phe-Thr-Ser-Cys with an internal disulfide bond) was characterized in subsequent biochemistry work, with the longer 28-residue form (somatostatin-28) recognized as a tissue-specific alternative processing product. The receptor-binding pharmacophore — the FWKT motif — became the basis for synthetic analog design over the following decades.
The synthetic somatostatin-analog era began with octreotide (Sandoz, FDA-approved 1988 as Sandostatin), an 8-residue cyclic analog (D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-ol with a cyclic structure stabilizing the FWKT-equivalent receptor-binding face). Octreotide's resistance to peptidase degradation extended the plasma half-life to roughly 100 minutes, enabling thrice-daily subcutaneous dosing — and the octreotide LAR (long-acting release) microsphere formulation introduced monthly intramuscular dosing. Octreotide rapidly became the standard-of-care for acromegaly (residual GH excess after pituitary surgery), neuroendocrine tumor symptom management (carcinoid syndrome, VIPoma, glucagonoma, insulinoma), and various off-label uses including post-operative pancreatic fistula prophylaxis (with mixed clinical-trial evidence) and chylothorax management.
Lanreotide (Somatuline, Ipsen) followed with a different cyclic analog backbone and a depot formulation enabling monthly autogel injection. The 2014 CLARINET trial established lanreotide's antiproliferative effect in metastatic enteropancreatic NETs — moving the class from symptom management to disease-modifying therapy. Pasireotide (Signifor, Novartis, FDA-approved 2012) added sst1 and sst3 receptor activity to the sst2/sst5 selectivity of octreotide and lanreotide — the broader receptor profile underlies pasireotide's efficacy in Cushing's disease (where sst5 expression on corticotroph adenomas enables ACTH suppression) and its different efficacy profile in some neuroendocrine tumor subtypes.
The peptide receptor radionuclide therapy (PRRT) era expanded the class beyond pure receptor agonism. Radiolabeled octreotide analogs — particularly 177Lu-DOTATATE (lutetium-177 DOTATATE, Lutathera) — bind sst2-expressing NET cells and deliver targeted beta-particle radiation, with the 2017 NETTER-1 NEJM trial establishing efficacy in metastatic midgut NETs and FDA approval following in 2018. Mycapssa (oral octreotide capsules, Chiasma/Amryt, FDA-approved 2020) introduced an oral formulation for acromegaly maintenance therapy.
Cortistatin's discovery in 1996 by de Lecea, Sutcliffe, and colleagues at Scripps (Nature 1996, see the Cortistatin peptide page) added an endogenous somatostatin paralog to the family — sharing the FWKT receptor-binding pharmacophore and broad sst1-sst5 agonism but with additional ghrelin-receptor antagonism and a distinctively cortical/hippocampal anatomical distribution. Cortistatin has not advanced to clinical development despite extensive preclinical interest from Mario Delgado and Elena Gonzalez-Rey at the Spanish CSIC in inflammatory disease applications.
State of evidence
Evidence in this class is among the most thoroughly developed in any peptide drug family. Multiple randomized controlled trials at thousands-of-patients scale, decades of real-world clinical experience, and well-characterized safety profiles establish octreotide, lanreotide, and pasireotide as standard-of-care agents in acromegaly, neuroendocrine tumor management, and Cushing's disease. Key trials include CLARINET (lanreotide antiproliferative efficacy in enteropancreatic NETs), PROMID (octreotide LAR antiproliferative efficacy in midgut NETs), NETTER-1 (177Lu-DOTATATE PRRT efficacy in metastatic midgut NETs), and various pasireotide pivotal trials in Cushing's and acromegaly. Pramlintide-style adoption barriers have not affected the somatostatin-analog class — these are well-established prescription drugs with substantial commercial and clinical presence.
The principal known safety concerns are: gallstones and biliary disease (a class effect from gallbladder contraction inhibition; many long-term users develop asymptomatic stones, with clinically significant disease less common); glucose dysregulation (more pronounced with pasireotide than octreotide/lanreotide because of sst5 effects on insulin secretion); gastrointestinal symptoms (diarrhea, bloating, malabsorption); injection-site reactions; rare bradycardia and conduction abnormalities. The QT prolongation signal that was a concern with the older somatostatin-analog literature has been characterized clinically and managed with appropriate monitoring.
How members compare
Within the family, the principal axes are receptor selectivity (octreotide/lanreotide sst2/sst5 vs pasireotide broader sst1/sst2/sst3/sst5) and dosing format (octreotide subcutaneous + LAR depot vs lanreotide depot autogel vs pasireotide subcutaneous + LAR vs Mycapssa oral vs Lutathera PRRT). For acromegaly: octreotide and lanreotide are interchangeable first-line; pasireotide is reserved for cases inadequate on first-generation analogs. For neuroendocrine tumor: lanreotide has the strongest antiproliferative evidence (CLARINET); octreotide LAR is the alternative; PRRT with 177Lu-DOTATATE is the disease-modifying option for metastatic midgut NETs progressing on first-line. For Cushing's disease: pasireotide is the somatostatin-analog option, used selectively due to the glucose-dysregulation profile.
Outside the somatostatin-analog family, the closest comparators depend on the indication. For acromegaly: GH-receptor antagonism with pegvisomant (Somavert) addresses cases inadequate on somatostatin analogs; cabergoline (a dopamine agonist) is an oral alternative for milder disease; pituitary surgery and stereotactic radiation cover the surgical/radiation tier. For neuroendocrine tumor management: PRRT (177Lu-DOTATATE), targeted therapies (everolimus, sunitinib), and chemotherapy (capecitabine/temozolomide, FOLFOX) round out the options. For Cushing's disease: ketoconazole, mifepristone, levoketoconazole, and other adrenal-steroidogenesis-inhibiting drugs plus pituitary surgery cover the alternatives to pasireotide.
Frequently asked questions
What's the difference between octreotide, lanreotide, and pasireotide?
All three are synthetic somatostatin-receptor agonists with different receptor selectivity and dosing profiles. Octreotide (Sandostatin, FDA 1988) and lanreotide (Somatuline, FDA 2007) have sst2/sst5 receptor selectivity — strong on the dominant pituitary somatotroph and NET receptors. Octreotide is available as subcutaneous (3x daily) and LAR (monthly intramuscular depot) and Mycapssa (oral); lanreotide is available as autogel (monthly subcutaneous depot). Both are first-line for acromegaly and NET management. Pasireotide (Signifor, FDA 2012) adds sst1 and sst3 activity to the sst2/sst5 profile — broader receptor coverage that produces efficacy in Cushing's disease (sst5 on corticotroph adenomas) but also more pronounced glucose dysregulation than octreotide/lanreotide. Pasireotide is positioned for Cushing's disease and for acromegaly cases inadequate on first-generation analogs.
Why do somatostatin analogs cause gallstones?
Somatostatin signaling inhibits gallbladder contraction (one of its many secretory-and-motor inhibitory effects). Chronic somatostatin-receptor agonism reduces gallbladder emptying, allowing bile to stagnate and concentrate — producing increased crystallization and gallstone formation. The effect is well-documented across the class with octreotide, lanreotide, and pasireotide. Many long-term users develop asymptomatic gallstones; clinically significant cholecystitis or biliary obstruction is less common. Patients on long-term somatostatin-analog therapy are typically monitored for gallbladder disease, and prophylactic ursodeoxycholic acid is sometimes used. The gallstone risk is one of the principal counseling points before starting these agents.
What are somatostatin analogs used for?
The principal FDA-approved indications are: acromegaly (residual growth hormone excess after pituitary surgery, or when surgery is not appropriate); neuroendocrine tumors (carcinoid syndrome symptom management with first-line analogs; antiproliferative therapy in metastatic enteropancreatic NETs based on CLARINET and PROMID trials; PRRT with 177Lu-DOTATATE in metastatic midgut NETs); Cushing's disease (pasireotide specifically, when surgery is inadequate); and various off-label uses including post-operative pancreatic fistula prophylaxis (mixed evidence), chylothorax management, gastrointestinal bleeding from variceal disease (somatostatin/octreotide, in combination with endoscopic intervention), and pituitary TSH-secreting adenoma. The class is fundamental to acromegaly and NET clinical care.
Is cortistatin the same as somatostatin?
No, but they are closely related. Cortistatin is an endogenous somatostatin paralog discovered in 1996 by de Lecea, Sutcliffe, and colleagues at the Scripps Research Institute. It shares 11 of 14 amino acids with somatostatin-14 (including the FWKT receptor-binding motif) and binds all five somatostatin receptors with similar affinity. The differences are: anatomical (cortistatin is selectively expressed in cortical and hippocampal GABAergic interneurons rather than the broad somatostatin distribution); pharmacological (cortistatin additionally binds the ghrelin receptor as an antagonist, the orphan MrgX2, and a cortistatin-preferring binding site); and functional (cortistatin promotes slow-wave sleep, an effect somatostatin doesn't produce). Cortistatin has not been clinically developed despite extensive preclinical interest from the Spanish CSIC group in inflammatory disease applications. See the Cortistatin peptide page for the full account.
How does PRRT (Lutathera) fit into this family?
Peptide receptor radionuclide therapy (PRRT) uses radiolabeled somatostatin analogs as targeting vehicles for radiation delivery to sst2-expressing tumor cells. 177Lu-DOTATATE (Lutathera, FDA-approved 2018 based on the NETTER-1 NEJM trial) couples a 177-lutetium beta-particle emitter to DOTATATE (an octreotide analog with sst2 selectivity), producing tumor-targeted radiation therapy with relatively limited off-target exposure. The mechanism — somatostatin-receptor binding plus radiation delivery — extends the class beyond pure receptor agonism into radiopharmaceutical territory. PRRT is the disease-modifying option for metastatic midgut NETs progressing on first-line octreotide LAR or lanreotide. The diagnostic counterpart 68Ga-DOTATATE PET scanning is the standard imaging tool for sst2-expressing NETs.
References
- Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormoneOriginal Research
Brazeau P, Vale W, Burgus R, Ling N, Butcher M, Rivier J, and Guillemin R, Science 1973. The discovery paper isolating somatostatin from sheep hypothalamus and demonstrating dose-dependent inhibition of pituitary growth hormone secretion. Foundational paper of the somatostatin family — earned Roger Guillemin a share of the 1977 Nobel Prize in Physiology or Medicine.